Key Takeaways
- FMC Corporation reported second-quarter 2026 revenue of $867 million, down 17% versus Q2 2025.
- The company posted a GAAP net loss of $187 million, compared with net income of $67 million a year earlier.
- FMC lowered its full-year 2026 guidance, now projecting revenue excluding India of $3.50 billion to $3.70 billion.
- The company said it has concluded the strategic review announced in February 2026 after securing roughly $1 billion in proceeds earmarked for debt reduction.
- Actions supporting the debt paydown include a $252 million sale of FMC’s India commercial business and a $200 million upfront payment from a rimisoxafen licensing deal with Corteva.
FMC Corporation Reports Lower Q2 2026 Revenue and Wider Losses
FMC Corporation (NYSE: FMC) reported second-quarter 2026 revenue of $867 million, down 17% from the same period last year. Revenue excluding the company’s India commercial business, which is held for sale, was $841 million, down 20%. On a GAAP basis, FMC posted a net loss of $187 million, compared with net income of $67 million in the second quarter of 2025, while adjusted EBITDA fell 26% to $153 million.
Company Lowers Full-Year Outlook
FMC lowered its full-year 2026 guidance, now projecting revenue excluding India of $3.50 billion to $3.70 billion, a 7% decline at the midpoint versus 2025. The company also lowered its adjusted EBITDA guidance to $620 million to $680 million and adjusted earnings per share guidance to $1.19 to $1.49. Free cash flow guidance was raised to $75 million to $225 million, reflecting a $200 million upfront payment tied to a rimisoxafen licensing agreement with Corteva.
FMC’s CEO on the Quarter
“During the quarter, we completed several important actions that strengthened FMC’s financial foundation and provide greater flexibility to execute our strategy. With the strategic review now concluded, we have clarity on the path forward and remain focused on improving competitiveness, advancing our technology portfolio and positioning the company for long-term growth,” said Pierre Brondeau, chairman, chief executive officer and president of FMC Corporation.
FMC Corporation Concludes Its Strategic Review
With debt-reduction actions now in place, the FMC board of directors has concluded the strategic review it announced in February 2026. Those actions include a definitive agreement to sell FMC’s India commercial business to Crystal Crop Protection Limited for $252 million, the $200 million upfront rimisoxafen licensing payment, a $114 million sale-leaseback of its Newark, Delaware property, and a $400 million equity investment from Tessenderlo Group. Combined with other minor asset sales, FMC expects to generate roughly $1 billion in proceeds for debt paydown.
